Just about everything in the top half is a regulatory decision or pivotal readout. The one exception is SERD '859 proof of concept at the top, however that same agent also has a pivotal readout as a monotherapy. So I don't think one can take a shot at the other proof of concepts including ST400 and BIV003 for appearing at the bottom of the list. These proof of concepts should be at the bottom below the regulatory and pivotal readouts.
Also we already know beta-thal had an issue(s) not related to editing. It's possible a correction or improvement was implemented prior to one of more sickle cell subjects being dosed. So mixed results from ST400 and BIV003 would be very good news as we could look forward to the improvement being implemented in beta-thal too.